{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Edema+Arm&page=2",
    "query": {
      "condition": "Edema Arm",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Edema+Arm&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T13:13:22.637Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05224102",
      "title": "A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2022-02-28",
      "completion_date": "2027-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Campbell, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05224102"
    },
    {
      "nct_id": "NCT04740905",
      "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema",
        "Branch Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 553,
      "start_date": "2021-03-02",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740905"
    },
    {
      "nct_id": "NCT01468831",
      "title": "Minocycline to Treat Branch Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-03-28",
      "completion_date": "2021-03-18",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01468831"
    },
    {
      "nct_id": "NCT02503540",
      "title": "Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinal Vein Occlusion",
        "Diabetic Macular Edema",
        "Branch Retinal Vein Occlusion",
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justis Ehlers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-08-18",
      "completion_date": "2018-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02503540"
    },
    {
      "nct_id": "NCT06041256",
      "title": "A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corneal Edema",
        "Corneal Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "AURN001",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Corneal Endothelial Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Y27632",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Aurion Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 97,
      "start_date": "2023-10-18",
      "completion_date": "2025-04-15",
      "has_results": true,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 17,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06041256"
    },
    {
      "nct_id": "NCT01982435",
      "title": "Safety and Efficacy of Ranibizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justis Ehlers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2014-06-24",
      "completion_date": "2016-05-26",
      "has_results": true,
      "last_update_posted_date": "2020-11-03",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01982435"
    },
    {
      "nct_id": "NCT05697809",
      "title": "Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "OXU-001",
          "type": "DRUG"
        },
        {
          "name": "Semi-automated suprachoroidal illuminated microcatheter",
          "type": "DEVICE"
        },
        {
          "name": "Ozurdex® Ophthalmic Intravitreal Implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Oxular Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2023-08-07",
      "completion_date": "2024-12-05",
      "has_results": true,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Clearwater, Florida • Oak Forest, Illinois + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Oak Forest",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05697809"
    },
    {
      "nct_id": "NCT06957080",
      "title": "A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "EYE103",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1054,
      "start_date": "2025-04-16",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 107,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06957080"
    },
    {
      "nct_id": "NCT06708637",
      "title": "Ocular Safety and Usability Study for FYB203 PFS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Branch Retinal Vein Occlusion with Macular Edema",
        "Central Retinal Vein Occlusion with Macular Edema",
        "Diabetic Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "FYB203 2 mg (0.05 mL of 40 mg/mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formycon AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-09-20",
      "completion_date": "2024-10-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 4,
      "location_summary": "Campbell, California • Long Beach, California • Redlands, California + 1 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708637"
    },
    {
      "nct_id": "NCT07118670",
      "title": "High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proliferative Diabetic Retinopathy (PDR)"
      ],
      "interventions": [
        {
          "name": "Aflibercept 8mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edward Wood, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-12-08",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-07-23T13:13:22.637Z",
      "location_count": 3,
      "location_summary": "Austin, Texas • Bellaire, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07118670"
    }
  ]
}